simendan has been researched along with Critical Illness in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthomieu, L; Bourgoin, P; Chenouard, A; Davril, E; Duflot, T; Joram, N; Lamoureux, F; Lecomte, J; Oualha, M; Pereira, T | 1 |
| Brochard, L; Doorduin, J; Frenzel, T; Heunks, L; Ottenheijm, C; Roesthuis, L; Sinderby, C; van der Hoeven, H | 1 |
| Lu, YQ; Pan, J; Yang, YM; Zhu, JY | 1 |
| Affronti, A; Bellani, G; Feri, M; Guarracino, F; Marini, M; Quacquarelli, A; Sangalli, F; Vitale, D; Volpi, F | 1 |
| Tritapepe, L | 1 |
| García-García, AE; Mena-Arceo, RG; Ñamendys-Silva, SA; Rojo Del Moral, O | 1 |
| Gordon, A; McAuley, DF; O'Kane, C; Prevost, AT; Santhakumaran, S; Shankar-Hari, M | 1 |
| Chang, XN; Chen, Y; Dong, CM; Feng, F; Li, M; Yuan, JJ | 1 |
| Huang, LQ; Huang, X; Jiang, RL; Lei, S; Xia, GL; Zhi, YH; Zhu, MF | 1 |
| Gluud, C; Keus, F; Koster, G; Scheeren, TW; van der Horst, IC; Wetterslev, J; Zijlstra, JG | 1 |
| Calabrò, MG; Covello, RD; Greco, M; Greco, T; Landoni, G; Morelli, A; Pasin, L; Zangrillo, A | 1 |
| Acea, AB; Ferrer Hita, JJ; García-González, MJ; Jiménez-Sosa, A; Jorge-Pérez, P; Lacalzada Almeida, JB | 1 |
| Yalta, K; Yilmaz, MB; Yontar, OC | 1 |
| Ajello, V; Bignami, E; Biondi-Zoccai, G; Guarracino, F; Landoni, G; Marino, G; Mizzi, A; Prati, P; Zangrillo, A | 1 |
| Bignami, E; Biondi-Zoccai, G; Greco, M; Greco, T; Guarracino, F; Landoni, G; Morelli, A; Zangrillo, A | 1 |
| Algotsson, L; Guarracino, F; Hörmann, C; Knotzer, J; Landoni, G; Lehmann, A; Rajek, A; Salmenperä, M; Schirmer, U; Toller, W; Tritapepe, L; Weis, F | 1 |
| Berger, R; Buberl, A; Delle Karth, G; Geppert, A; Heinz, G; Huelsmann, M; Kopp, C; Neunteufl, T; Nikfardjam, M | 1 |
| Graham, CA | 1 |
| Plöchl, W; Rajek, A | 1 |
| Butt, WW; Crossland, DS; Namachivayam, P; Shekerdemian, LS | 1 |
9 review(s) available for simendan and Critical Illness
| Article | Year |
|---|---|
Multiorgan Drug Action of Levosimendan in Critical Illnesses.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Critical Illness; Humans; Myocardial Contraction; Myocardium; Randomized Controlled Trials as Topic; Simendan | 2019 |
Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis.
Topics: Critical Illness; Female; Humans; Male; Sepsis; Shock, Septic; Simendan | 2019 |
Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Comorbidity; Critical Illness; Dobutamine; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Hypotension; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Survival Rate; Treatment Outcome | 2013 |
Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.
Topics: Cardiac Output, Low; Cardiotonic Agents; Critical Illness; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2015 |
A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.
Topics: Bayes Theorem; Cardiac Surgical Procedures; Critical Illness; Dobutamine; Enoximone; Humans; Hydrazones; Milrinone; Pyridazines; Simendan; Vasodilator Agents | 2015 |
Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies.
Topics: Cardiotonic Agents; Critical Illness; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2010 |
Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
Topics: Cardiac Surgical Procedures; Critical Care; Critical Illness; Female; Heart Failure; Hospital Mortality; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Risk Assessment; Simendan; Treatment Outcome | 2012 |
Perioperative use of levosimendan: best practice in operative settings.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Critical Illness; Humans; Hydrazones; Perioperative Care; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Surgical Procedures, Operative | 2013 |
Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
Topics: Acute Disease; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Critical Illness; Developed Countries; Diuretics; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Oxygen Inhalation Therapy; Patient Selection; Pulmonary Edema; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2004 |
3 trial(s) available for simendan and Critical Illness
| Article | Year |
|---|---|
Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation.
Topics: Critical Illness; Double-Blind Method; Electromagnetic Phenomena; Humans; Muscle Weakness; Pressure; Respiration, Artificial; Respiratory Muscles; Simendan; Ventilator Weaning | 2019 |
Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Critical Illness; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Recovery of Function; Severity of Illness Index; Simendan; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
Topics: Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Critical Illness; Dopamine; Drug Therapy, Combination; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Pyridazines; Shock, Cardiogenic; Simendan; Vasodilator Agents; Ventricular Function, Left | 2003 |
8 other study(ies) available for simendan and Critical Illness
| Article | Year |
|---|---|
Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation.
Topics: Anti-Bacterial Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Infant, Newborn; Prospective Studies; Simendan | 2023 |
Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions.
Topics: Critical Illness; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Shock, Cardiogenic; Simendan | 2020 |
Does levosimendan improve weaning outcome? It does much more.
Topics: Critical Illness; Humans; Hydrazones; Pyridazines; Simendan; Weaning | 2020 |
Organ Function Assessment, Prevention, and Outcomes in Critically Ill Patients with Sepsis.
Topics: Critical Illness; Humans; Multiple Organ Failure; Organ Dysfunction Scores; Sepsis; Simendan | 2018 |
Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents; APACHE; Cardiotonic Agents; Critical Illness; Female; Guideline Adherence; Hospital Mortality; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Male; Middle Aged; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Sepsis; Simendan; Simvastatin; Treatment Outcome; Vasoconstrictor Agents; Vasopressins | 2019 |
Superiority of levosimendan over dobutamine in right ventricle failure.
Topics: Cardiotonic Agents; Critical Care; Critical Illness; Dobutamine; Female; Heart Function Tests; Humans; Hydrazones; Hypertension, Pulmonary; Intensive Care Units; Male; Myocardial Infarction; Prognosis; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Vascular Resistance; Ventricular Dysfunction, Right | 2010 |
The use of the novel calcium sensitizer levosimendan in critically ill patients.
Topics: Aged; Cardiac Output; Cardiac Output, High; Cardiotonic Agents; Critical Illness; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Postoperative Complications; Pyridazines; Simendan; Stroke Volume; Vascular Resistance; Vasodilator Agents | 2004 |
Early experience with Levosimendan in children with ventricular dysfunction.
Topics: Adolescent; Cardiac Output, Low; Cardiotonic Agents; Catecholamines; Child; Child, Preschool; Cohort Studies; Critical Illness; Humans; Hydrazones; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Ultrasonography; Ventricular Dysfunction | 2006 |